Global 23-Valent Pneumococcal Polysaccharide Vaccine Sales Market Report 2020

23-Valent Pneumococcal Polysaccharide Vaccine is a kind of vaccine used to prevent infection caused by pneumococcal bacteria. 23-Valent Pneumococcal Polysaccharide Vaccine contains 23 of the most common types of pneumococcal bacteria.

23-Valent Pneumococcal Polysaccharide Vaccine is for use only in adults and children who are at least 2 years old. For children younger than 2 years old, another vaccine called Prevnar (pneumococcal conjugate vaccine [PCV] 7-valent) is used, usually given between the ages of 2 months and 15 months.
North America is the largest supplier and consumption market of 23-Valent Pneumococcal Polysaccharide Vaccine, with a production market share nearly 70% and sales market share nearly 28% in 2015. Because Sanofipasteur, a competitor from Europe, transferred its vaccine type gradually, the production market share of North America in the world has enjoyed a dramatic increase.

Market Analysis and Insights: Global 23-Valent Pneumococcal Polysaccharide Vaccine Market
The global 23-Valent Pneumococcal Polysaccharide Vaccine market size is projected to reach US$ 5330.9 million by 2026, from US$ 2378.2 million in 2020, at a CAGR of 14.4% during 2021-2026.

Global 23-Valent Pneumococcal Polysaccharide Vaccine Scope and Market Size
The global 23-Valent Pneumococcal Polysaccharide Vaccine market is segmented by company, region (country), by Type, and by Application. Players, stakeholders, and other participants in the global 23-Valent Pneumococcal Polysaccharide Vaccine market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on sales, revenue and forecast by region (country), by Type and by Application for the period 2015-2026.

Segment by Type, the 23-Valent Pneumococcal Polysaccharide Vaccine market is segmented into
Single Dose Vial
Pre-filled Syringe

Segment by Application, the 23-Valent Pneumococcal Polysaccharide Vaccine market is segmented into
For Children (2-10)
For Person (10-64)
For The Old (≥65)

The 23-Valent Pneumococcal Polysaccharide Vaccine market is analysed and market size information is provided by regions (countries). Segment by Application, the 23-Valent Pneumococcal Polysaccharide Vaccine market is segmented into United States, Europe, China, Japan, Southeast Asia, India and Rest of World.
The report includes region-wise market size for the period 2015-2026. It also includes market size and forecast by players, by Type, and by Application segment in terms of sales and revenue for the period 2015-2026.

Competitive Landscape

and 23-Valent Pneumococcal Polysaccharide Vaccine Market Share Analysis
23-Valent Pneumococcal Polysaccharide Vaccine market competitive landscape provides details and data information by players. The report offers comprehensive analysis and accurate statistics on revenue by the player for the period 2015-2020. It also offers detailed analysis supported by reliable statistics on revenue (global and regional level) by players for the period 2015-2020. Details included are company description, major business, company total revenue and the sales, revenue generated in 23-Valent Pneumococcal Polysaccharide Vaccine business, the date to enter into the 23-Valent Pneumococcal Polysaccharide Vaccine market, 23-Valent Pneumococcal Polysaccharide Vaccine product introduction, recent developments, etc.

The major vendors covered:
MSD
Sanofipasteur
CDIBP